The dual T-cell agonist invikafusp alfa achieved a 50% DCR in heavily pretreated anti–PD-1/PD-L1–resistant tumors, per findings at the 2024 SITC Annual Meeting.
8hon MSN
Personalized medicine is revolutionizing lung cancer treatment by tailoring approaches to genetic profiles, leading to more ...
If you or a loved one is considering participating in a cancer clinical trial, this 10-step guide will help you navigate the ...
CFIUS — it’s not a new disease making people sick, an ancient Greek mythological figure or a planet in another galaxy. CFIUS ...
The rate of infections with the flu-like human metapneumovirus (HMPV) in northern China is declining, a health official said Sunday, amid some international concern over a potential ...
A 10-year-old went over the embankment off of Northcliffe Drive in Atlanta while sledding. He was rushed to the hospital with a leg injury.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback